“深圳赛百诺是中国生物制药产业突破的特例,”深圳科兴生物副总经理何询说。在中国生物制药产业与美欧差距扩大的情况下,2004年10月深圳赛百诺“重组人p53腺病毒注射液”基因治疗药物生产基地开工建设。除生物制药之外,包括传统的中药与化学制药、生物医学工程在内的深圳整个生物医药产业在2004年新出台的政府产业规划下寻求更大的发展。 “Shenzhen Saibeno is a special case of a breakthrough in China’s biopharmaceutical industry,” said He Qunsheng, deputy director of Shenzhen Kexing Bio. With the widening gap between the biopharmaceutical industry in China and the United States and Europe, Shenzhen Sembcorp Gene Recombinant Human p53 Adenovirus Injection drug production base was under construction in October 2004. In addition to biopharmaceuticals, the entire biopharmaceutical industry in Shenzhen, including traditional Chinese medicine, chemical pharmacy and biomedical engineering, is seeking further development under the newly introduced government industrial plan in 2004.